Zhong-Rui Ma1, Li-Jun Shi2. 1. Department of Neurology, Chengdu Fifth People's Hospital Chengdu, China. 2. Department of Hematology, Chengdu Fifth People's Hospital Chengdu, China.
Abstract
BACKGROUND AND OBJECTIVE: Randomized controlled trials (RCTs) on repetitive transcranial magnetic stimulation (rTMS) as augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD) have yielded conflicting results. Therefore, this meta-analysis was conducted to assess the efficacy of this strategy for SSRI-resistant OCD. METHODS: Scientific and medical databases, including international databases (PubMed, MEDLINE, EMBASE, CCTR, Web of Science, PsycINFO), two Chinese databases (CBM-disc, CNKI), and relevant websites dated up to July 2014, were searched for RCTs on this strategy for treating OCD. Mantel-Haenszel random-effects model was used. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score, response rates and drop-out rates were evaluated. RESULTS: Data were obtained from nine RCTs consisting of 290 subjects. Active rTMS was an effective augmentation strategy in treating SSRI-resistant OCD with a pooled WMD of 3.89 (95% CI = [1.27, 6.50]) for reducing Y-BOCS score and a pooled odds ratio (OR) of 2.65 (95% CI = [1.36, 5.17] for response rates. No significant differences in drop-out rates were found. No publication bias was detected. CONCLUSION: The pooled examination demonstrated that this strategy seems to be efficacious and acceptable for treating SSRI-resistant OCD. As the number of RCTs included here was limited, further large-scale multi-center RCTs are required to validate our conclusions.
BACKGROUND AND OBJECTIVE: Randomized controlled trials (RCTs) on repetitive transcranial magnetic stimulation (rTMS) as augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD) have yielded conflicting results. Therefore, this meta-analysis was conducted to assess the efficacy of this strategy for SSRI-resistant OCD. METHODS: Scientific and medical databases, including international databases (PubMed, MEDLINE, EMBASE, CCTR, Web of Science, PsycINFO), two Chinese databases (CBM-disc, CNKI), and relevant websites dated up to July 2014, were searched for RCTs on this strategy for treating OCD. Mantel-Haenszel random-effects model was used. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score, response rates and drop-out rates were evaluated. RESULTS: Data were obtained from nine RCTs consisting of 290 subjects. Active rTMS was an effective augmentation strategy in treating SSRI-resistant OCD with a pooled WMD of 3.89 (95% CI = [1.27, 6.50]) for reducing Y-BOCS score and a pooled odds ratio (OR) of 2.65 (95% CI = [1.36, 5.17] for response rates. No significant differences in drop-out rates were found. No publication bias was detected. CONCLUSION: The pooled examination demonstrated that this strategy seems to be efficacious and acceptable for treating SSRI-resistant OCD. As the number of RCTs included here was limited, further large-scale multi-center RCTs are required to validate our conclusions.
Authors: P Alonso; J Pujol; N Cardoner; L Benlloch; J Deus; J M Menchón; A Capdevila; J Vallejo Journal: Am J Psychiatry Date: 2001-07 Impact factor: 18.112
Authors: Peter G Enticott; Bernadette M Fitzgibbon; Hayley A Kennedy; Sara L Arnold; David Elliot; Amy Peachey; Abraham Zangen; Paul B Fitzgerald Journal: Brain Stimul Date: 2013-10-27 Impact factor: 8.955
Authors: Miguel A Fullana; David Mataix-Cols; Avshalom Caspi; Honalee Harrington; Jessica R Grisham; Terrie E Moffitt; Richie Poulton Journal: Am J Psychiatry Date: 2009-02-02 Impact factor: 18.112
Authors: Alexandra Kammen; Jonathon Cavaleri; Jordan Lam; Adam C Frank; Xenos Mason; Wooseong Choi; Marisa Penn; Kaevon Brasfield; Barbara Van Noppen; Stuart B Murray; Darrin Jason Lee Journal: Front Neurol Date: 2022-08-09 Impact factor: 4.086